2024
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
Sanoff H, Deal A, Patel J, Sorah J, Gaddy J, O’Neil B, Turk A, Irvin W, Boles J, Lee M, McRee A, Wardell A, Weck K, Basch E, Wood W, Innocenti F. A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The Oncologist 2024, oyae122. PMID: 38837045, DOI: 10.1093/oncolo/oyae122.Peer-Reviewed Original ResearchProgression-free survivalMetastatic colorectal cancerOverall survivalIrinotecan doseColorectal cancerMedian progression-free survivalMetastatic colorectal cancer patientsEstimates of overall survivalFirst-line settingUnresectable colorectal cancerRates of neutropeniaFirst-line therapyPhase II trialPatient-reported adverse eventsRate of diarrheaG3/4 toxicitiesUGT1A1 genotypeIrinotecan metabolismFirst-linePrimary endpointSecondary endpointsAdverse eventsFOLFIRIHistorical controlsNon-genotype
2022
Integrated approach to collecting patient reported toxicities in a colorectal cancer trial.
Gaddy J, Sanoff H, Deal A, Basch E, Wood W. Integrated approach to collecting patient reported toxicities in a colorectal cancer trial. Journal Of Clinical Oncology 2022, 40: 51-51. DOI: 10.1200/jco.2022.40.4_suppl.051.Peer-Reviewed Original ResearchDose decreaseSevere symptomsToxicity ratesSevere toxicityClinical trialsGenotype-guided dosing strategyAppropriate dose modificationPRO-CTCAEStandard drug dosesAdverse event assessmentMulti-center clinical trialClinically relevant issuesColorectal cancer trialsHematologic toxicityMCRC patientsDose modificationAbdominal painAdvanced CRCToxicity gradeCycling patientsClinical characteristicsDosing strategiesAdverse eventsDrug doseClinician grading